PSIL

AdvisorShares Psychedelics ETF [PSIL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PSIL Stock Summary

Top PSIL Correlated Resources

PSIL

Top 10 Correlated ETFs

PSIL

Top 10 Correlated Stocks

PSIL

In the News

PSIL Financial details

Company Rating
-
Market Cap
7.06M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
0.22%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-4.75%
SMA50
-23.29%
SMA100
-4.35%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.26-2.249
52W High
+468.5%
52W Low
+1037%
RSI
48.89
Rel Volume
0.05
Avg Volume
69.41K
Volume
3.8K
Perf Week
3.27%
Perf Month
-6.5%
Perf Quarter
-5.17%
Perf Half Y
-10.82%
-
-
-
-
Beta
0.956477
-
-
Volatility
0.22%, 0.71%
Prev Close
0.53%
Price
11.37
Change
0.71%

PSIL Financial Performance

PSIL Dividend History

PSIL Frequently Asked Questions

What is AdvisorShares Psychedelics ETF stock symbol ?

AdvisorShares Psychedelics ETF is a US stock and trading under the symbol PSIL

What is AdvisorShares Psychedelics ETF stock quote today ?

AdvisorShares Psychedelics ETF stock price is $11.37 today.

Is AdvisorShares Psychedelics ETF stock public?

Yes, AdvisorShares Psychedelics ETF is a publicly traded company.

Something similar

Top by Market Cap
JPM
M&M.NS
MSFT
VTI
MIX.JO
Top Correlated ETFs
SBIO
IDNA
XBI
BBC
WDNA
Top Correlated Stocks
ALT
SID
RIO
SCCO
PTCT
Similar Market Cap
CEY
ADMP
RUEH.TO
DBMM
MYRX

Company Profile

Financial Services Asset Management

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.